205 related articles for article (PubMed ID: 38498726)
21. Antithrombin III-Binding Site Analysis of Low-Molecular-Weight Heparin Fractions.
Chen Y; Zhao J; Yu Y; Liu X; Lin L; Zhang F; Linhardt RJ
J Pharm Sci; 2018 May; 107(5):1290-1295. PubMed ID: 29339133
[TBL] [Abstract][Full Text] [Related]
22. Combinatorial one-pot chemoenzymatic synthesis of heparin.
Bhaskar U; Li G; Fu L; Onishi A; Suflita M; Dordick JS; Linhardt RJ
Carbohydr Polym; 2015 May; 122():399-407. PubMed ID: 25817684
[TBL] [Abstract][Full Text] [Related]
23. Preparation of low molecular weight heparins from bovine and ovine heparins using nitrous acid degradation.
Xie S; Guan Y; Zhu P; Li F; Yu M; Linhardt RJ; Chi L; Jin L
Carbohydr Polym; 2018 Oct; 197():83-91. PubMed ID: 30007661
[TBL] [Abstract][Full Text] [Related]
24. Chemoenzymatic Synthesis of Glycosaminoglycans.
Zhang X; Lin L; Huang H; Linhardt RJ
Acc Chem Res; 2020 Feb; 53(2):335-346. PubMed ID: 31714740
[TBL] [Abstract][Full Text] [Related]
25. Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin.
Jeske W; Kouta A; Duff R; Rangnekar V; Niverthi M; Hoppensteadt D; Fareed J; Yao Y
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):150S-156S. PubMed ID: 30198315
[TBL] [Abstract][Full Text] [Related]
26. A purification process for heparin and precursor polysaccharides using the pH responsive behavior of chitosan.
Bhaskar U; Hickey AM; Li G; Mundra RV; Zhang F; Fu L; Cai C; Ou Z; Dordick JS; Linhardt RJ
Biotechnol Prog; 2015; 31(5):1348-59. PubMed ID: 26147064
[TBL] [Abstract][Full Text] [Related]
27. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
[TBL] [Abstract][Full Text] [Related]
28. Characterization of currently marketed heparin products: analysis of molecular weight and heparinase-I digest patterns.
Sommers CD; Ye H; Kolinski RE; Nasr M; Buhse LF; Al-Hakim A; Keire DA
Anal Bioanal Chem; 2011 Nov; 401(8):2445-54. PubMed ID: 21901459
[TBL] [Abstract][Full Text] [Related]
29. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan.
Maddineni J; Ma Q; Hoppensteadt DA; Demir M; Manoni M; Cornelli U; Fareed J
Clin Appl Thromb Hemost; 2004 Jan; 10(1):27-37. PubMed ID: 14979402
[TBL] [Abstract][Full Text] [Related]
30. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
31. Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins.
St Ange K; Onishi A; Fu L; Sun X; Lin L; Mori D; Zhang F; Dordick JS; Fareed J; Hoppensteadt D; Jeske W; Linhardt RJ
Clin Appl Thromb Hemost; 2016 Sep; 22(6):520-7. PubMed ID: 27084870
[TBL] [Abstract][Full Text] [Related]
32. Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin.
Baytas SN; Varghese SS; Jin W; Yu Y; He P; Douaisi M; Zhang F; Brodfuehrer P; Xia K; Dordick JS; Linhardt RJ
J Med Chem; 2021 Feb; 64(4):2242-2253. PubMed ID: 33586962
[TBL] [Abstract][Full Text] [Related]
33. Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins.
Xu Y; Masuko S; Takieddin M; Xu H; Liu R; Jing J; Mousa SA; Linhardt RJ; Liu J
Science; 2011 Oct; 334(6055):498-501. PubMed ID: 22034431
[TBL] [Abstract][Full Text] [Related]
34. Analysis of 3-O-sulfo group-containing heparin tetrasaccharides in heparin by liquid chromatography-mass spectrometry.
Li G; Yang B; Li L; Zhang F; Xue C; Linhardt RJ
Anal Biochem; 2014 Jun; 455():3-9. PubMed ID: 24680753
[TBL] [Abstract][Full Text] [Related]
35. Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin.
Baik JY; Dahodwala H; Oduah E; Talman L; Gemmill TR; Gasimli L; Datta P; Yang B; Li G; Zhang F; Li L; Linhardt RJ; Campbell AM; Gorfien SF; Sharfstein ST
Biotechnol J; 2015 Jul; 10(7):1067-81. PubMed ID: 26037948
[TBL] [Abstract][Full Text] [Related]
36. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.
Koenig A; Norgard-Sumnicht K; Linhardt R; Varki A
J Clin Invest; 1998 Feb; 101(4):877-89. PubMed ID: 9466983
[TBL] [Abstract][Full Text] [Related]
37. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
Schick BP; Maslow D; Moshinski A; San Antonio JD
Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
[TBL] [Abstract][Full Text] [Related]
38. Engineered heparins as new anticoagulant drugs.
Vaidyanathan D; Williams A; Dordick JS; Koffas MAG; Linhardt RJ
Bioeng Transl Med; 2017 Mar; 2(1):17-30. PubMed ID: 28516163
[TBL] [Abstract][Full Text] [Related]
39. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
40. Fragment profiling of low molecular weight heparins using reversed phase ion pair liquid chromatography-electrospray mass spectrometry.
Xu X; Li D; Chi L; Du X; Bai X; Chi L
Carbohydr Res; 2015 Apr; 407():26-33. PubMed ID: 25701653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
